Zusammenfassung
Das Nebennierenrindenkarzinom ist häufig ein sehr aggressiver Tumor, dessen Pathogenese weitgehend ungeklärt ist. Die Einteilung dieser seltenen uroonkologischen Krebserkrankung beruht auf der TNM-Klassifikation. Dieses Kapitel beschreibt neben Risikofaktoren das diagnostische Vorgehen – Hormondiagnostik, Ausbreitungs- und Target-spezifische Diagnostik, Bildgebung. Das therapeutische Vorgehen differenziert zwischen der Therapie des lokal begrenzten und des fortgeschrittenen Nebennierenrindenkarzinoms. Die Prognose dieses urologischen Malignoms ist ebenso dargelegt wie Empfehlungen zur Nachsorge.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Abraham J, Bakke S, Rutt A et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94: 2333–2343
Allolio B, Hahner S, Weismann D et al. (2004) Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60: 273–287
Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM (2011) Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 96 (12): 3775–3784
Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M and Baudin E (2007). Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92 (1): 148–54
Baudin E, Pellegriti G, Bonnay M et al. (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 1385–1392
Becherer A, Vierhapper H, Potzi C et al. (2001) FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 16: 289–295
Berruti A, Terzolo M, Pia A et al. (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83: 2194–2200
Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M; German Adrenocortical Carcinoma Registry Group. (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58 (4): 609–615
Caoili EM, Korobkin M, Francis IR et al. (2000) Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 175: 1411–1415
Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B (/2009) Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 160 (6): 1003–1010
Fassnacht M, Hahner S, Banfelder N et al. (2005) Diagnostik und Therapie des Nebennierenrinden-Karzinoms. DÄ 102: 1670–1675
Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M and Allolio B (2006). Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91 (11): 4501–4
Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B (2010) Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 95 (11): 4925–32
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115 (2): 243–250
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B (2012) Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med 2012 [Epub ahead of print]
Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, Beuschlein F, Zink M, Lang K, Allolio B and Schirbel A (2008). [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab 93 (6): 2358–65
Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65 (4): 765–773
Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E (2011) Plasma concentrations of o, p’DDD, o, p’DDA, and o, p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96 (6): 1844–51
Jain M, Rechache N, Kebebew E (2012) Molecular markers of adrenocortical tumors. J Surg Oncol [Epub ahead of print]
Khan TS, Imam H, Juhlin C et al. (2000) Streptozocin and o, p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11: 1281–1287
Lau SK, Weiss LM (2009) The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Human Pathol 40: 757–768
Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 162 (6): 1147–1153
Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI (2010) The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 46 (4): 713–719
Pena CS, Boland GW, Hahn PF et al. (2000) Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217: 798–802
Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritte C, Strasburger C, Allolio B and Fassnacht M (2008). Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93 (6): 2057–62
Saeger W (2000) Histopathological classification of adrenal tumours. Eur J Clin Invest 30 Suppl 3: 58–62
Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M and Worden FP (2005). Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12 (3): 667–680
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17 (2): 445–453
Terzolo M, Ali A, Osella G et al. (2000) The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. Eur J Endocrinol 142: 611–617
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L and Berruti A (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356 (23): 2372–80
Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd (2010) Adrenocortical carcinoma: the influence of large vessel extension. Surgery 148 (6): 1057–1064
Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13: 202–206
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Petersenn, S., Mann, K., Nagarajah, I., Bockisch, A., Rübben, H. (2014). Nebennierenrindenkarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-35032-0_18
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35031-3
Online ISBN: 978-3-642-35032-0
eBook Packages: Medicine (German Language)